RISK ASSESSMENTS 35 3-CMC - Report on the risk assessment of

87 2 RISK ASSESSMENT REPORT I 3-CMC Acknowledgements The EMCDDA would like to thank the following for their contribution in producing this publication: the members of the extended Scientific Committee of the EMCDDA; the advisers to the Scientific Committee and the invited external experts who took part in the risk assessment meeting, in particular: o Dr Piotr Adamowicz, Institute of Forensic Res. [...] The Risk Assessment Report, which was submitted to the European Commission on 25 November 2021, examines the health and social risks of the drug, information on international trafficking and the involvement of organised crime, as well as a consideration of the potential implications of subjecting the drug to control measures. [...] On the basis of the Risk Assessment Report, the Commission adopted delegated act in order to add 3-CMC in to the definition of a drug in the Annex of the Council Framework Decision 2004/757/JHA (as amended by Directive (EU) 2017/2103). [...] In accordance with Article 5c of the Regulation, the meeting to assess the risks of 3-CMC was convened under the auspices of the Scientific Committee of the EMCDDA with the participation of six additional experts designated by the Director of the EMCDDA, acting on the advice of the Chairperson of the Scientific Committee, chosen from a list of experts approved by the Management Board of the EMCDDA. [...] The risk assessment was carried out on the basis of information provided to the Scientific Committee by the Member States, the EMCDDA, Europol, the EMA, the European Centre for Disease Prevention and Control (ECDC), the European Chemicals Agency (ECHA), and the European Food Safety Authority (EFSA).